Expression of programmed cell death ligand-1 in mastocytosis correlates with disease severity
Authors:
- 1 January 2016
- journal article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 137 (1) , 314-318.e5
Abstract
No abstract availableFunding Information
- German Research Council (HA 2393/6-1)
- Koeln Fortune Program (308/2014)
This publication has 8 references indexed in Scilit:
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's LymphomaNew England Journal of Medicine, 2015
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 TherapyClinical Cancer Research, 2014
- Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosisJournal of Allergy and Clinical Immunology, 2013
- Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patientsJournal of Allergy and Clinical Immunology, 2013
- PD-1 Regulates the Growth of Human Mastocytosis CellsAllergology International, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patientsJournal of Allergy and Clinical Immunology, 2009